The Shepherd Paris (van Dyck) in the Wallace Collection. It was acquired by Henry Hope prior to 1807 before being bought by Francis Charles Seymour-Conway, 3rd Marquess of Hertford when the Hope collection was sold at Christie's on 29 June 1816. At that time, it was thought to be a self-portrait of van Dyck himself. The Marquess intended to bequeath the painting to George IV but he outlived the king and was unable to do so. The Shepherd Paris (van Dyck) The Shepherd Paris is a c.1628 painting by the Flemish artist Anthony van Dyck, dating to just after the artist's return from Italy and
Christopher H. van Dyck brain. Studies of this ligand in early Alzheimer’s Disease patients have shown a loss of synapses from the perforant path, the connections between the entorhinal cortex and hippocampal formation needed for memory consolidation. van Dyck and the Yale ADRU have tested potential Alzheimer’s therapeutics for over 20 years. They have contributed to the successful development of memantine now in use for the treatment of mid-late stage Alzheimer’s Disease, and assess potential new therapeutic strategies, e.g. antibodies that reduce amyloid pathology such as Crenezumab, and based on the work of Dr. Stephen Strittmatter, an inhibitor of fyn. Dr. van Dyck serves